Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AFL6 | ISIN: US87164F1057 | Ticker-Symbol: 1T3
Stuttgart
27.06.25 | 08:02
7,950 Euro
+2,58 % +0,200
1-Jahres-Chart
SYNDAX PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
SYNDAX PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
7,6007,80013:03
7,5007,90027.06.

Aktuelle News zur SYNDAX PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoSyndax Pharmaceuticals-Direktor William Meury tritt nach neuer CEO-Rolle bei Incyte zurück6
DoSyndax Pharmaceuticals Inc - 8-K, Current Report-
SYNDAX PHARMACEUTICALS Aktie jetzt für 0€ handeln
MiFDA Grants Priority Review To Syndax's Revuforj For R/R MNPM1 Acute Myeloid Leukemia Treatment-
DiSyndax Pharmaceuticals, Inc.: Syndax Announces FDA Priority Review of sNDA for Revuforj (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia76- PDUFA action date set for October 25, 2025 - - sNDA being reviewed under FDA's RTOR program - - Revumenib has the potential to become the first and only menin inhibitor approved in both R/R mNPM1...
► Artikel lesen
12.06.Syndax Pharmaceuticals, Inc.: Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 20254
12.06.Syndax Pharmaceuticals, Inc.: Syndax Presents New Revuforj (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 20252
05.06.Syndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)95NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on June...
► Artikel lesen
05.06.Syndax Pharmaceuticals auf der Jefferies-Konferenz: Strategisches Wachstum und Expansion2
28.05.Syndax Pharmaceuticals auf dem 6. Jährlichen Onkologie-Innovationsgipfel: Strategische Einblicke2
16.05.Syndax Pharmaceuticals Inc - 8-K, Current Report2
14.05.Syndax Pharmaceuticals, Inc.: Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj (revumenib) and Niktimvo (axatilimab-csfr)8
12.05.Syndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer188- Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R&D strategy and global commercialization of novel oncology therapeutics - NEW...
► Artikel lesen
06.05.Scotiabank raises Syndax stock target to $17 on strong sales6
06.05.BofA raises Syndax stock price target to $26 on strong Q1 update8
06.05.Syndax pharmaceuticals outlines $750M opportunity for Revuforj in initial market2
05.05.Syndax Q1 2025 slides: Revuforj revenue hits $20M, cash position remains strong2
05.05.Syndax Pharmaceuticals, Inc.: Syndax Reports First Quarter 2025 Financial Results and Provides Business Update237- $20.0 million in Revuforj® (revumenib) net revenue in first full quarter of launch - - $13.6 million in Niktimvo (axatilimab-csfr) net revenue (reported by Incyte) in first partial quarter of launch...
► Artikel lesen
05.05.Syndax Pharmaceuticals Inc - 10-Q, Quarterly Report1
05.05.Syndax Pharmaceuticals Inc - 8-K, Current Report1
02.05.Syndax Pharmaceuticals Q1 2025 Earnings Preview6
Weiter >>
53 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1